466 related articles for article (PubMed ID: 19039139)
21. Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.
Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993848
[TBL] [Abstract][Full Text] [Related]
22. NLCQ-1 and NLCQ-2, two new agents with activity against dormant Mycobacterium tuberculosis.
Papadopoulou MV; Bloomer WD; McNeil MR
Int J Antimicrob Agents; 2007 Jun; 29(6):724-7. PubMed ID: 17379483
[TBL] [Abstract][Full Text] [Related]
23. Pretomanid for the treatment of pulmonary tuberculosis.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2020 Oct; 56(10):655-668. PubMed ID: 33185630
[TBL] [Abstract][Full Text] [Related]
24. The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.
Patterson S; Wyllie S; Stojanovski L; Perry MR; Simeons FR; Norval S; Osuna-Cabello M; De Rycker M; Read KD; Fairlamb AH
Antimicrob Agents Chemother; 2013 Oct; 57(10):4699-706. PubMed ID: 23856774
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Thompson AM; Blaser A; Anderson RF; Shinde SS; Franzblau SG; Ma Z; Denny WA; Palmer BD
J Med Chem; 2009 Feb; 52(3):637-45. PubMed ID: 19099398
[TBL] [Abstract][Full Text] [Related]
26. Adduct Formation of Delamanid with NAD in Mycobacteria.
Hayashi M; Nishiyama A; Kitamoto R; Tateishi Y; Osada-Oka M; Nishiuchi Y; Kaboso SA; Chen X; Fujiwara M; Inoue Y; Kawano Y; Kawasaki M; Abe T; Sato T; Kaneko K; Itoh K; Matsumoto S; Matsumoto M
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152081
[TBL] [Abstract][Full Text] [Related]
27. Release of nitrite from the antitubercular nitroimidazole drug PA-824 and analogues upon one-electron reduction in protic, non-aqueous solvent.
Maroz A; Shinde SS; Franzblau SG; Ma Z; Denny WA; Palmer BD; Anderson RF
Org Biomol Chem; 2010 Jan; 8(2):413-8. PubMed ID: 20066278
[TBL] [Abstract][Full Text] [Related]
28. Coenzyme F
Purwantini E; Loganathan U; Mukhopadhyay B
J Bacteriol; 2018 Dec; 200(23):. PubMed ID: 30249701
[TBL] [Abstract][Full Text] [Related]
29. 3D-QSAR and cell wall permeability of antitubercular nitroimidazoles against Mycobacterium tuberculosis.
Lee SH; Choi M; Kim P; Myung PK
Molecules; 2013 Nov; 18(11):13870-85. PubMed ID: 24217328
[TBL] [Abstract][Full Text] [Related]
30. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents.
Hurdle JG; Lee RB; Budha NR; Carson EI; Qi J; Scherman MS; Cho SH; McNeil MR; Lenaerts AJ; Franzblau SG; Meibohm B; Lee RE
J Antimicrob Chemother; 2008 Nov; 62(5):1037-45. PubMed ID: 18693235
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824.
Li X; Manjunatha UH; Goodwin MB; Knox JE; Lipinski CA; Keller TH; Barry CE; Dowd CS
Bioorg Med Chem Lett; 2008 Apr; 18(7):2256-62. PubMed ID: 18358721
[TBL] [Abstract][Full Text] [Related]
32. Maximizing bactericidal activity with combinations of bioreduced drugs.
Goldman RC
Future Med Chem; 2010 Aug; 2(8):1253-71. PubMed ID: 21426017
[TBL] [Abstract][Full Text] [Related]
33. Molecule Property Analyses of Active Compounds for
Makarov V; Salina E; Reynolds RC; Kyaw Zin PP; Ekins S
J Med Chem; 2020 Sep; 63(17):8917-8955. PubMed ID: 32259446
[TBL] [Abstract][Full Text] [Related]
34. Dual Mechanism of Action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis.
Kidwai S; Park CY; Mawatwal S; Tiwari P; Jung MG; Gosain TP; Kumar P; Alland D; Kumar S; Bajaj A; Hwang YK; Song CS; Dhiman R; Lee IY; Singh R
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28893784
[TBL] [Abstract][Full Text] [Related]
35. Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis.
Gold B; Roberts J; Ling Y; Quezada LL; Glasheen J; Ballinger E; Somersan-Karakaya S; Warrier T; Warren JD; Nathan C
Antimicrob Agents Chemother; 2015 Oct; 59(10):6521-38. PubMed ID: 26239979
[TBL] [Abstract][Full Text] [Related]
36. Delamanid is not metabolized by Salmonella or human nitroreductases: A possible mechanism for the lack of mutagenicity.
Hanaki E; Hayashi M; Matsumoto M
Regul Toxicol Pharmacol; 2017 Mar; 84():1-8. PubMed ID: 27988333
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Palmer BD; Thompson AM; Sutherland HS; Blaser A; Kmentova I; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
J Med Chem; 2010 Jan; 53(1):282-94. PubMed ID: 19928920
[TBL] [Abstract][Full Text] [Related]
38. DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid.
Abrahams KA; Batt SM; Gurcha SS; Veerapen N; Bashiri G; Besra GS
Nat Commun; 2023 Jun; 14(1):3828. PubMed ID: 37380634
[TBL] [Abstract][Full Text] [Related]
39. Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic Bacteria.
Zhuang Z; Wan D; Ding J; He S; Zhang Q; Wang X; Yuan Y; Lu Y; Ding CZ; Lynch AS; Upton AM; Cooper CB; Denny WA; Ma Z
Molecules; 2020 May; 25(10):. PubMed ID: 32456032
[TBL] [Abstract][Full Text] [Related]
40. Pharmacophore modeling and density functional theory analysis for a series of nitroimidazole compounds with antitubercular activity.
Tawari NR; Degani MS
Chem Biol Drug Des; 2011 Sep; 78(3):408-17. PubMed ID: 21689377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
